This bill mandates that the New Hampshire Medicaid program provide coverage for biomarker testing under specific conditions. It introduces a new subdivision to the Managed Care Law, defining key terms such as "biomarker," "biomarker testing," "clinical utility," "consensus statements," and "nationally recognized clinical practice guidelines." The bill stipulates that biomarker testing will be covered when deemed medically necessary for diagnosis, treatment, management, or monitoring of a beneficiary's condition, supported by various forms of medical evidence, including FDA indications and clinical guidelines.

Additionally, the bill outlines the requirements for prior authorization processes and ensures that beneficiaries and healthcare providers have access to a clear procedure for requesting exceptions to coverage policies. It also emphasizes that coverage should limit disruptions in care and specifies that the provisions will only take effect if sufficient funding is included in the operating budget for the FY28/29 biennium. The bill is set to take effect on July 1, 2027, and anticipates an increase in state expenditures ranging from $170,000 to $600,000 annually, with additional federal funding.